Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
October 18 2017 - 08:00AM
Business Wire
- Company expects to report topline eight-week
results at the end of the year -
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in treating
aesthetic and therapeutic conditions, today announced it has
completed enrollment of patients in the Company’s Phase 2 program
investigating the use of DaxibotulinumtoxinA for Injection (RT002)
for the management of plantar fasciitis. The study enrolled 59
subjects across five centers in the United States (US). The Company
remains on track to report 8-week topline results at the end of
this year, including the primary and secondary endpoints, along
with safety data.
“One in 10 people will develop plantar fasciitis pain in their
lifetime and more than two million patients in the US undergo
treatment annually. No neuromodulator has been approved for the
treatment of this debilitating pain indication and current
treatments do not provide fast, sustained pain relief,” said Dan
Browne, President and Chief Executive Officer at Revance. “RT002 is
unlike any other neuromodulator, with potential to provide improved
outcomes and patient experience over existing treatments. We are
eager to report topline data for plantar fasciitis before year
end.”
Phase 2 Study Design
This Phase 2 prospective, randomized, double-blind,
placebo-controlled, multi-center study conducted at five centers in
the US is evaluating the safety and efficacy of a single
administration of Revance’s investigational drug candidate
DaxibotulinumtoxinA for Injection (RT002) in reducing the signs and
symptoms of plantar fasciitis. The study’s primary efficacy
endpoint is the reduction in the visual analog scale (VAS) for pain
in the foot evaluated at Week 8. Improvement in the American
Orthopaedic Foot and Ankle Score (AOFAS) is one of several
secondary endpoints. Subjects will be followed for a total of 16
weeks post treatment.
About Plantar Fasciitis
Heel pain is the most common complaint of patients who visit
podiatrists and orthopaedic foot and ankle surgeons. Eighty percent
of reported heel pain complaints are due to plantar fasciitis,
which is caused by tears in the facia that in turn lead to
inflammation of the connective tissue in the arch of the foot.1
Plantar fasciitis is estimated to affect 10 to 18 million
individuals in the United States annually.2 Risk factors include
age, long distance running, excessive weight, abnormal foot
posture, use of poor foot wear, and repetitive trauma.3
Treatment options for less severe cases include leg and foot
stretching exercises, nonsteroidal anti-inflammatory drugs, shoe
inserts, heel pads, and night splints. More severe or refractory
cases are currently treated with steroid injections, extracorporeal
shock wave therapy, platelet rich plasma injections, and/or
surgery.4
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance’s
initial focus is on developing daxibotulinumtoxinA, the company’s
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company’s lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with the
potential to be the first long-acting neuromodulator. The company
holds worldwide rights to RT002 injectable and RT001 topical and
the pharmaceutical uses of its proprietary peptide technology
platform. More information on Revance may be found
at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related the process and timing of, and ability
to complete, current and anticipated future clinical development of
our investigational drug product candidates, including but not
limited to initiation and design of clinical studies for current
and future indications, related results and reporting of such
results; statements about our business strategy, timeline and other
goals and market for our anticipated products, plans and prospects;
and statements about our ability to obtain regulatory approval; and
potential benefits of our drug product candidates and our
technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risk that clinical trials may
not have an effective design or generate positive results; our
ability to obtain and maintain regulatory approval of our drug
product candidates; our ability to obtain funding for our
operations; our plans to research, develop, and commercialize our
drug product candidates; our ability to achieve market acceptance
of our drug product candidates; unanticipated costs or delays in
research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the
size and growth potential of the markets for our drug product
candidates; our ability to successfully commercialize our drug
product candidates and the timing of commercialization activities;
the rate and degree of market acceptance of our drug product
candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange
Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our quarterly report on Form
10-Q filed August 4, 2017. These forward-looking statements speak
only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.
References:
1. Med Clin N America. 2014;98(2): 339-352. 2. Foot & Ankle
Int. 2004;25(5):303-310. 3. Foot & Ankle Int. 2008 Mar;
29(3):358-366. 4. J Am Acad Orthop Surg. 2014;22(6):372-380.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171018005475/en/
Investors:Revance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorTrade Media, Inc.:For
Revance Therapeutics, Inc.:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2023 to Mar 2024